CRP and rheumatoid arthritis: For RA, the findings highlight the potential of PUFAs to reduce disease activity (measured by DAS28), inflammatory biomarkers (CRP, ESR, IL-6), and NSAID use, while also modulating lipid and glucose metabolism (27, 30, 35, 40, 41).